...
首页> 外文期刊>Journal of Surgical Oncology >Prevention of complications following pelvic exenteration with the use of mammary implants in the pelvic cavity: Technique and results of 28 cases.
【24h】

Prevention of complications following pelvic exenteration with the use of mammary implants in the pelvic cavity: Technique and results of 28 cases.

机译:在盆腔中使用乳房植入物在盆腔内进行骨盆外部术后预防并发症:技术和结果28例。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: With the evolution of neo-adjuvant therapy and the introduction of peritonectomy with chemotherapy in surgical practice, pelvic exenteration has taken second place in the treatment of advanced pelvic tumors. This surgery remains the first of choice for the treatment of T4 superior and medium rectal tumors that are not susceptible to neo-adjuvant radiochemotherapy, for uterine tumors and cervical FIGO IV T4, for pelvic recurrence and for T4 bladder tumors. After a pelvic exenteration the pelvic cavity becomes occupied by the intestinal loops, causing an increase in the risk of short and long-term complications such as radiation enteritis in the case of post-operative radiotherapy, occlusions, and enteric fistulas that could be avoided by isolating the small intestine in the pelvic cavity. METHODS: With this aim we positioned a mammary prosthesis (implant) in the cavity of the last 28 cases we treated, and did not observe complications related to the prosthetic implant. RESULTS: No early or delayed complications, such as occlusions or fistulas, were observed. All the patients treated underwent adjuvant radiotherapy with no evidence of radiation enteritis. Ten patients were recanalized with removal of the implant, ultra-low rectal anastomosis was performed in six cases and colo-anal anastomosis was performed in four cases. Eight patients were not recanalized, six distance due to recurrence and two local recurrence. Nine patients are currently in follow-up, disease free between 1 and 12 months. CONCLUSIONS: We retain the encouraging results observed that the use of mammary implants in the pelvic cavity after pelvic exenteration should be part of the cultural patrimony of the surgeon who approaches this type of major radical surgery.
机译:背景:随着新辅助治疗的演变和腹膜切除术治疗手术实践中的化疗,盆腔出口已经在治疗晚期骨盆肿瘤时占据了第二个地方。这种手术仍然是治疗T4优越和中等直肠肿瘤的首选,这些肿瘤不容易受到新辅助的放射化学疗法,用于子宫肿瘤和颈椎纤维图IV T4,用于盆腔复发和T4膀胱肿瘤。在盆腔内出现后,盆腔腔被肠道环占据,导致术后放疗后的辐射肠炎的短期和长期并发症的风险增加,可以避免分离骨盆腔中的小肠。方法:目的是,我们将乳房假体(植入物)定位在我们对治疗的最后28例患者的腔中,并没有观察到与假体植入物相关的并发症。结果:未观察到早期或延迟并发症,例如闭塞或瘘管。所有患者都治疗了辅助放疗没有辐射肠炎的证据。 10名患者重新加入植入物,在六种情况下进行超低直肠吻合术,并在四种情况下进行Colo-Anaastomoss。八名患者没有重新进入,由于复发和两种局部复发导致六个距离。九名患者目前处于随访,无病1至12个月。结论:我们保留了令人鼓舞的结果,观察到骨盆外部后骨盆腔中使用乳腺植入物应该是接近这种类型的主要自由基手术的外科医生的文化遗产的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号